Article Information
History
- April 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Rupali Sharma1,
- Bhargav Earla1,2,
- Kwamena Baidoo3,
- Martha A. Zeiger4,
- James P. Madigan1,
- Freddy E. Escorcia3 and
- Samira M. Sadowski1,*
- 1Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
- 2UAB Heersink School of Medicine, 1670 University Blvd, Birmingham, AL, USA
- 3Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
- 4Office of Surgeon Scientists Programs, Center for Cancer Research, National Cancer Institute, NIH, Bldg 31, Bethesda, MD, USA
- ↵*Corresponding author: Samira M. Sadowski, MD Physician-Scientist Early Investigator Head Neuro-endocrine Cancer Therapy Section Endocrine Surgery Section Surgical Oncology Program National Cancer Institute, NIH 10 Center Drive, Bldg 10, Rm 4-5932 Bethesda, MD 20892 Office: 240-858-3413 Fax: 301-451-5580 Email: samira.sadowski{at}nih.gov
Posted April 26, 2022.
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
